Effects of different molecular weight hyaluronan products on the expression of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis

Journal of Orthopaedic Research

Volumn 26, Issue 4, 2008, Pages 475-484

  Hsieh, Yih Shou ^a   Yang, Shun Fa ^a   Lue, Ko Huang ^a   Chu, Shu Chen ^b   Lu, Ko Hsiu ^a,c  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Gelatinase; Hyaluronic acid; Molecular weight; Osteoarthritis; Plasminogen activator and inhibitor

Indexed keywords

GELATINASE; GELATINASE A; GELATINASE B; HYALURONIC ACID; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE; UROKINASE RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; CARTILAGE CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; KNEE MENISCUS; MALE; MOLECULAR WEIGHT; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SYNOVIUM; ZYMOGRAPHY; CHEMISTRY; COMPARATIVE STUDY; KNEE OSTEOARTHRITIS; METABOLISM; MIDDLE AGED; TISSUE CULTURE TECHNIQUE;

AGED; FEMALE; HUMANS; HYALURONIC ACID; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MOLECULAR WEIGHT; OSTEOARTHRITIS, KNEE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE CULTURE TECHNIQUES; URINARY PLASMINOGEN ACTIVATOR;

EID: 41649105563     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20524     Document Type: Article

References (52)

1. Hedbom E, Hauselmann HJ. 2002. Molecular aspects of pathogenesis in osteoarthritis: the role of inflammation. Cell Mol Life Sci 59:45-53.
2. Pelletier JP, Martel-Pelletier J, Howell DS. 2000. Etiopathogenesis of osteoarthritis. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology, 14th ed. Baltimore: Williams & Wilkins. p 2195-2245.
3. Dreier R, Grassel S, Fuchs S, et al. 2004. Pro-MMP-9 is a specific macrophage product and is activated by osteo-arthritic chondrocytes via MMP-3 or a MT1-MMP/MMP-13 cascade. Exp Cell Res 297:303-312.
4. Hsieh YS, Yang SF, Chu SC, et al. 2004. Expression changes of gelatinases in human osteoarthritic knees and arthroscopic debridement. Arthroscopy 20:482-488.
5. Murphy G, Knauper V, Atkinson S, et al. 2002. Matrix metalloproteinases in arthritic disease. Arthritis Res 4 (Suppl 3):S39-S49.
6. Chu SC, Yang SF, Lue KH, et al. 2004. Regulation of gelatinases expression by cytokines, endotoxin, and pharmacological agents in the human osteoarthritic knee. Connect Tissue Res 45:142-150.
7. Irigoyen JP, Munoz-Canoves P, Montero L, et al. 1999. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 56:104-132.
8. Mazzieri R, Masiero L, Zanetta L, et al. 1997. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16:2319-2332.
9. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, et al. 1999. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274:13066-13076.
10. Andreasen PA, Georg B, Lund LR, et al. 1990. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 68:1-19.
11. Kikuchi H, Tanaka S, Matsuo O. 1987. Plasminogen activator in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 14:439-445.
12. Matsuo O, Tanaka S, Kikuchi H. 1988. Effect of urinary trypsin inhibitor on osteoarthritis. Thromb Res 52:237-245.
13. Chu SC, Yang SF, Lue KH, et al. 2004. The clinical significance of gelatinase B in gouty arthritis of the knee. Clin Chim Acta 339:77-83.
14. Koolwijk P, Miltenburg AM, van Erck MG, et al. 1995. Activated gelatinase-B (MMP-9) and urokinase-type plasminogen activator in synovial fluids of patients with arthritis. Correlation with clinical and experimental variables of inflammation. J Rheumatol 22:385-393.
15. Lu KH, Yang SF, Chu SC, et al. 2004. The significance of altered gelatinase expression in the synovium of patient with arthritic effusions. Clin Rheumatol 23:21-26.
16. Chu SC, Yang SF, Lue KH, et al. 2006. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee. J Rheumatol 33:311-317.
17. Chu SC, Yang SF, Lue KH, et al. 2004. Clinical significance of gelatinases in septic arthritis of native and replaced knees. Clin Orthop Relat Res 427:179-183.
18. Hsieh YS, Yang SF, Lue KH, et al. 2006. Clinical correlation with the PA/plasmin system in septic arthritis of the knee. Clin Orthop Relat Res 447:172-178.
19. Hsieh YS, Yang SF, Lue KH, et al. 2007. Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis. J Rheumatol 34:785-793.
20. Takahashi K, Goomer RS, Harwood F, et al. 1999. The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1beta (IL-1beta), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis Cartilage 7:182-190.
21. Nonaka T, Kikuchi H, Ikeda T, et al. 2000. Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis. J Rheumatol 27:997-1004.
22. Takahashi K, Hashimoto S, Kubo T, et al. 2001. Hyaluronan suppressed nitric oxide production in the meniscus and synovium of rabbit osteoarthritis model. J Orthop Res 19:500-503.
23. Kikuchi T, Denda S, Yamaguchi T. 1993. Effect of sodium hyaluronate (SL-1010) on glycosaminoglycan synthesis and release in rabbit articular cartilage. Jpn Pharmacol Ther 127:157.
24. Tobetto K, Yasui T, Ando T, et al. 1992. Inhibitory effects of hyaluronan on [14C]arachidonic acid release from labeled human synovial fibroblasts. Jpn J Pharmacol 60:79-784.
25. Ghosh P, Guidolin D. 2002. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum 32:10-37.
26. Clegg PD, Jones MD, Carter SD. 1998. The effect of drugs commonly used in the treatment of equine articular disorders on the activity of equine matrix metalloprotei-nase-2 and 9. J Vet Pharmacol Ther 21:406-413.
27. Balazs EA, Watson D, Duff IF, et al. 1967. Hyaluronic acid in synovial fluid. I. Molecular parameters of hyaluronic acid in normal and arthritis human fluids. Arthritis Rheum 10:357-376.
28. Kang Y, Eger W, Koepp H, et al. 1999. Hyaluronan suppresses fibronectin fragment-mediated damage to human cartilage explant cultures by enhancing proteogly-can synthesis. J Orthop Res 17:858-869.
29. Williams JM, Plaza V, Hui F, et al. 1997. Hyaluronic acid suppresses fibronectin fragment mediated cartilage chondrolysis: II. In vivo. Osteoarthritis Cartilage 5:235-240.
30. Chu SC, Yang SF, Lue KH, et al. 2006. Glucosamine sulfate suppresses the expressions of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis. Clin China Acta 372:167-172.
31. Kleiner DE, Stetler-Stevenson WG. 1994. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 218:325-329.
32. Makowski GS, Ramsby ML. 1996. Calibrating gelatin zymograms with human gelatinase standards. Anal Biochem 236:353-356.
33. Maneiro E, de Andres MC, Fernandez-Sueiro JL, et al. 2004. The biological action of hyaluronan on human osteoartritic articular chondrocytes: the importance of molecular weight. Clin Exp Rheumatol 22:307-312.
34. Buckwalter JA. 2005. Musculoskeketal tissues and the musculoskeletal system. In: Weinstein SL, Buckwalter JA, editors. Turek's orthopaedics: principles and their application, 6th ed. Philadelphia: Lippincott, William & Wilkins. p 3-56.
35. Cheras PA, Whitaker AN, Blackwell EA, et al. 1997. Hypercoagulability and hypofibrinolysis in primary osteoarthritis. Clin Orthop Relat Res 334:57-67.
36. Martel-Pelletier J, Faure MP, McCollum R, et al. 1991. Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage. J Rheumatol 18:1863-1871.
37. Collen D. 1999. The plasminogen (fibrinolytic) system. Thromb Haemost 82:259-270.
38. Busso N, Peclat V, So A, et al. 1997. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 56:550-557.
39. Pelletier JP, Mineau F, Fernandes J, et al. 1997. Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts. Clin Exp Rheumatol 15:393-398.
40. Pelletier JP, Mineau F, Faure MP, et al. 1990. Imbalance between the mechanisms of activation and inhibition of metalloproteases in the early lesions of experimental osteoarthritis. Arthritis Rheum 33:1466-1476.
41. Sternlicht MD, Werb Z. 2001. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463-516.
42. Adams ME, Atkinson MH, Lussier AJ, et al. 1995. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multi-center trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage 3:213-225.
43. Weiss C, Band P. 1995. Musculoskeletal applications of hyaluronan and hylan. Potential uses in the foot and ankle. Clin Podiatr Med Surg 12:497-517.
44. Balazs EA. 1982. The physical properties of synovial fluid and the special role of hyaluronic acid. In: Helfet AJ, editor. Disorders of the knee, 2nd ed. Philadelphia: J.B. Lippincott. p 61-74.
45. Lo GH, LaValley M, McAlindon T, et al. 2003. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 290:3115-3121.
46. Wang CT, Lin J, Chang CJ, et al. 2004. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J Bone Joint Surg [Am] 86-A:538-545.
47. Hamburger MI, Lakhanpal S, Mooar PA, et al. 2003. Intra-articular hyaluronans: a review of product-specific safety profiles. Semin Arthritis Rheum 32:296-309.
48. Bellamy N, Campbell J, Robinson V, et al. 2005. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2: CD005321.
49. Gomis A, Pawlak M, Balazs EA, et al. 2004. Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthritis Rheum 50:314-326.
50. Miyake K, Underhill CB, Lesley J, et al. 1990. Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J Exp Med 172:69-75.
51. Goldberg VM, Buckwalter JA. 2005. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthritis Cartilage 13: 216-224.
52. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. 2000. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 43:1905-1915.